Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Insmed Inc INSM

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).


NDAQ:INSM - Post by User

Bullboard Posts
Post by scissors14on Sep 02, 2004 9:27am
123 Views
Post# 7877704

INSM On A Tear!

INSM On A Tear! agree that the stock was way oversold, touched nearly a dollar. It has come back with a vengeance. The market manipulation is hard to take but I averaged down and am near breakeven again. Tobin Smith says the following: Our diabetes home-run stock we are tracking a variety of companies in the diabetes industry, and this company is one of the most promising aggressive names. The idea behind this pick is simple. These guys own the patented intellectual property for a hormone replacement therapy that helps control diabetes almost like magic. The market for hormone replacement therapies is huge, with growth hormones representing a billion-dollar market and insulin being a $2 billion-plus sector. This company owns the "key" to safely deliver insulin-like proteins that can greatly improve life quality (and even mean the difference between life and death). Management believes -- and our Research Alliance concurs -- that their compound, called SomatoKine, has a $1 billion annual market potential. Why? Simply put, this compound helps diabetics reduce their use of insulin -- dramatically in some cases. That's an incredible breakthrough in the treatment of this dread disease. What's more, this drug recently received "orphan drug designation" as a treatment for extreme insulin resistance. This gives the compound preferential treatment. And it's the first step to the FDA approval for ALL diabetics -- and that, my friend, is the promised land. I've seen similar breakthrough therapies shoot stocks sky-high before. Avastin, a cancer therapy, added $5 billion in market cap to Genentech. And the scientific principle behind this firm's SomatoKine treatment is quite similar -- and could easily bring the same result. Keep in mind that this play is aggressive and volatile. But the reward I'm seeking is equally exciting. I'm targeting another ten-bagger by late 2005-early 2006! Remember, this is a Legacy Stock, which means you buy this one with risk-capital and learn to ignore day-to-day price fluctuations. You're buying this for a result we believe will come in a couple of years, not months. But we also are convinced it will be well worth the wait!
Bullboard Posts